Aprea Therapeutics annual stock-based compensation
2017
2018
2019
2020
2022
2023
2024
2025
Aprea Therapeutics Stock-Based Compensation Growth & History (APRE)
Aprea Therapeutics's stock-based compensation was $478,141 for fiscal 2025.
View full Aprea Therapeutics company overviewAprea Therapeutics annual stock-based compensation history
| Fiscal year | Period ended | Stock-based compensation | Change | Growth |
|---|---|---|---|---|
| 2025 | 2025-12-31 | $478,141 | −$11,295 | −2.31% |
| 2024 | 2024-12-31 | $489,436 | $44,977 | +10.12% |
| 2023 | 2023-12-31 | $444,459 | −$16.5M | −97.38% |
| 2022 | 2022-12-31 | $17.0M | — | — |
| 2020 | 2020-12-31 | $5.0M | $3.6M | +270.29% |
| 2019 | 2019-12-31 | $1.3M | $1.0M | +308.02% |
| 2018 | 2018-12-31 | $329,814 | −$65,626 | −16.60% |
| 2017 | 2017-12-31 | $395,440 | — | — |
Aprea Therapeutics quarterly stock-based compensation
Q3.18
Q1.19
Q2.19
Q3.19
Q4.19
Q1.20
Q2.20
Q3.20
Q4.20
Q1.21
Q2.21
Q3.21
Q1.22
Q2.22
Q3.22
Q1.23
Q2.23
Q3.23
Q1.24
Q2.24
Q3.24
Q1.25
Q2.25
Q3.25
Q4.25
Q1.26
Q2.26
| Fiscal quarter | Period ended | Stock-based compensation | Change | YoY change |
|---|---|---|---|---|
| Q2 2026 | 2026-06-30 | $100,000 | $0 | 0.00% |
| Q1 2026 | 2026-03-31 | $101,068 | $1,068 | +1.07% |
| Q4 2025 | 2025-12-31 | $109,024 | — | — |
| Q3 2025 | 2025-09-30 | $100,000 | −$49,090 | −32.93% |
| Q2 2025 | 2025-06-30 | $100,000 | −$28,488 | −22.17% |
| Q1 2025 | 2025-03-31 | $100,000 | $0 | 0.00% |
| Q3 2024 | 2024-09-30 | $149,090 | $73,059 | +96.09% |
| Q2 2024 | 2024-06-30 | $128,488 | −$140,835 | −52.29% |
| Q1 2024 | 2024-03-31 | $100,000 | $83,756 | +515.61% |
| Q3 2023 | 2023-09-30 | $76,031 | $37,795 | +98.85% |
| Q2 2023 | 2023-06-30 | $269,323 | −$14.5M | −98.18% |
| Q1 2023 | 2023-03-31 | $16,244 | −$2.1M | −99.23% |
| Q3 2022 | 2022-09-30 | $38,236 | −$2.0M | −98.12% |
| Q2 2022 | 2022-06-30 | $14.8M | $12.9M | +694.21% |
| Q1 2022 | 2022-03-31 | $2.1M | $277,438 | +15.22% |
| Q3 2021 | 2021-09-30 | $2.0M | $646,944 | +46.55% |
| Q2 2021 | 2021-06-30 | $1.9M | $607,038 | +48.31% |
| Q1 2021 | 2021-03-31 | $1.8M | $917,091 | +101.28% |
| Q4 2020 | 2020-12-31 | $1.4M | $616,857 | +75.73% |
| Q3 2020 | 2020-09-30 | $1.4M | $1.1M | +464.38% |
| Q2 2020 | 2020-06-30 | $1.3M | $1.1M | +572.04% |
| Q1 2020 | 2020-03-31 | $905,471 | $807,525 | +824.46% |
| Q4 2019 | 2019-12-31 | $814,588 | — | — |
| Q3 2019 | 2019-09-30 | $246,225 | $166,434 | +208.59% |
| Q2 2019 | 2019-06-30 | $186,963 | — | — |
| Q1 2019 | 2019-03-31 | $97,946 | — | — |
| Q3 2018 | 2018-09-30 | $79,791 | — | — |
Aprea Therapeutics stock-based compensation trends
Over the last five fiscal years, Aprea Therapeutics's stock-based compensation decreased from $5.0M to $478,141, a change of −$4.5M. The latest reported quarter, Q2 2026, shows $100,000.
About the metric
What stock-based compensation means
Stock-based compensation is the expense associated with equity awards such as restricted stock and employee options. It is a non-cash expense when recognized, but it can dilute existing shareholders unless offset by share repurchases.
Calculation and source
SEC-reported stock-based compensation
TickerStat standardizes share-based compensation reported in company SEC filings. The history shows recognized compensation expense or its cash-flow-statement adjustment, not the grant-date value of new awards or a forecast of future dilution. Fiscal periods can differ from calendar years, so exact period-end dates are included.
Review Aprea Therapeutics source filings ↗